The Tough Tech problem we are solving
Antibodies protect us from external pathogens by binding invaders, such as bacteria, viruses and parasites, and functionally activating the cellular immune system. This system can malfunction, however, when people develop antibodies that inappropriately interact with their own tissues (autoantibodies) or respond to harmless substances in food or the environment.
These misdirected (or ‘pathogenic’) antibodies can lead to a wide range of serious diseases such as autoimmune diseases, metabolic imbalances and allergies. However, current treatments for autoimmune diseases are non-specific, often have poor efficacy and come with a risk of serious side effects.
About our solution
Our novel platform aims to target and eliminate the pathogenic drivers of antibody-driven diseases with unprecedented precision and durability to address the root cause of disease and achieve durable clinical responses.
We engineer highly-selective Fc biotherapeutics to target the antibodies driving autoimmune and allergic diseases. Our therapeutic approach not only binds these pathogenic antibodies selectively, but immediately directs them to specialized liver cells for lysosomal degradation and inhibits the B cells that produce them, resulting in their durable elimination.